Thu, Aug 21, 2014, 7:14 AM EDT - U.S. Markets open in 2 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Nov 13, 2013 11:01 AM Flag

    Serapta's blow-up, AF's Mea Culpa

    The Street and Cramer should be really embarrassed! This is some of what Falsestein had to say after losing his readers/followers millions of dollars:
    "How did I get Sarepta wrong? Without a doubt, I have been a Sarepta supporter and a believer in eteplirsen. My biggest mistake: Having more confidence in the tiny, 12-patient eteplirsen phase II study than I should have.

    In my defense, I was clear about the higher regulatory risk facing Sarepta following the failure of GlaxoSmithKline (GSK_) and Prosensa's (RNA_) drisapersen phase III study. What I didn't anticipate was FDA "rejecting" eteplirsen before the drug was even filed.

    My worst-case scenario was Sarepta filing eteplirsen based on the phase II study, FDA reviewing the application but then rejecting the drug with a request for a confirmatory phase III study. I didn't anticipate FDA not allowing the early filing to happen at all. Tuesday's scenario was not something I thought would happen. Big mistake.

    I also allowed emotion and anecdotal evidence of eteplirsen's efficacy to cloud my judgment. I usually admonish investors for investing in a drug stock based on a personal story. I violated my own rule with Sarepta. "

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
13.45-0.28(-2.04%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.